Bilateral Retinal Venous Occlusion in Atypical Hemolytic-Uremic Syndrome Due to Complement Factor H Mutation.
| Autor: | Gonul S; Department of Ophthalmology, Selcuk University Faculty of Medicine, Konya, Turkey., Eker S; Department of Ophthalmology, Isparta Yalvaç State Hospital, Isparta, Turkey. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Ocular immunology and inflammation [Ocul Immunol Inflamm] 2024 Nov; Vol. 32 (9), pp. 2285-2289. Date of Electronic Publication: 2024 Mar 27. |
| DOI: | 10.1080/09273948.2024.2333401 |
| Abstrakt: | Purpose: Atypical hemolytic uremic syndrome (aHUS) is a rare progressive thrombotic microangiopathy caused by overactivation in the alternative complement pathway. A wide spectrum of environmental triggers, such as viruses, vaccination, drugs, pregnancy, neoplasms, transplant, and autoimmune diseases can cause aHUS in genetically susceptible individuals. In this report, the diagnosis and treatment process of aHUS and bilateral retinal venous occlusion (RVO) will be presented. Methods: Single-case, retrospective management of ophthalmological and systemic manifestations. Results: A 28-year-old G2P2 female with acute blurred vision and history of acute renal failure. She was diagnosed with preeclampsia in her gestation history. After the laboratory work-up, the diagnosis of aHUS was confirmed. She was treated with eculizumab following 14 days of plasmapheresis. However, her visual acuity was 20/20 on the right and 20/60 on the left at the time of admission. Retinal examination revealed flame-shaped hemorrhages, exudation, and macular edema. The patient was diagnosed with branch RVO in the right eye. Subsequently, central RVO was occurred in the left eye. Intravitreal dexamethasone implant was administered for both eyes since there was no reasonable regression in retinal findings with bevacizumab treatment. She went into remission and her BCVA reached 20/25 during the 12-month follow-up period under the eculizumab therapy. Conclusion: Diagnosis of aHUS is challenging especially during pregnancy and the postpartum period. Although ocular involvement is quite rare, we described bilateral RVO in aHUS case with homozygous nonsense mutation (c.2134 G > T p.G712). Dexamethasone implant should be considered for the treatment of RVO in aHUS cases. |
| Databáze: | MEDLINE |
| Externí odkaz: |
|